galiximab
mAbexperimental
Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials. The drug is a chimeric antibody from Macaca irus and Homo sapiens. — Wikipedia
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Jan 1, 2002 (NCT00575068)
Timeline
Indications
Mechanism of action
- T-lymphocyte activation antigen CD80INHIBITOR
CD80 inhibitor
Antibody-dependent cell-mediated cytotoxicity (ADCC).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGaliximab ↗
- ChEMBLCHEMBL2109191 ↗
Also known as
- anti-b7-1 mab
- anti-cd80 monoclonal antibody
- galiximab
- galiximab
- galiximab
- galiximab
- idec-114
- idec-114
- idec-114
- p-16c10
- primatized anti-b7 antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00651443 | Phase 1 | Aug 1, 2008 | Biogen |
| NCT00516217 | Phase 2 | Jun 1, 2008 | National Cancer Institute (NCI), University of Chicago |
| NCT00384150 | Phase 3 | Nov 1, 2007 | Biogen |
| NCT00363636 | Phase 3 | Sep 1, 2006 | Biogen |
| NCT00117975 | Phase 2 | Jun 1, 2005 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT00048555 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2002 | Biogen |
| NCT00575068 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2002 | Biogen |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 5 | 5 | 3 | 2002 |
| National Cancer Institute (NCI) | Government | 2 | 2 | 1 | 2005 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2008 |
4 organizations
Page 1 / 1